Vedolizumab

Vedolizumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	integrin α4β7
Identifiers
CAS Number	943609-66-3
ATC code	none
Chemical data
Formula	C6528H10072N1732O2042S42
Molar mass	146.8 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vedolizumab is a monoclonal antibody being developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.^[1] It binds to integrin α₄β₇ (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1)^[1]^[2]

As of October 2009^[update], vedolizumab is undergoing Phase III trials.^[3]

References

↑ ^1.0 ^1.1 Statement On A Nonproprietary Name Adopted By The USAN Council - Vedolizumab, American Medical Association.
↑ Soler, D; Chapman, T; Yang, LL; Wyant, T; Egan, R; Fedyk, ER (2009). "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases". 330 (3): 864–75. doi:10.1124/jpet.109.153973. PMID 19509315. Text "journal: The Journal of pharmacology and experimental therapeutics" ignored (help)
↑ ClinicalTrials.gov NCT00790933 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (GEMINI II)

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

v t e Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (immune system)	immunosuppressive: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-immunosuppressive: Ibalizumab^†
"-bazu-" (bacterial)	Tefibazumab^†
"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toxazu-" (toxin as target)	Urtoxazumab
"-vizu-" (viral)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin as target)	Lebrikizumab
"-anibizu-" (angiogenesis inhibitor)	Ranibizumab
^†Undergoing clinical trials. ^§Never marketed.